Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Fingolimod in RRMS
NCT01497262Phase 3Completed
- Sponsor
- Novartis
- Start
- Feb 2012
- Primary completion
- Apr 2014
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of fingolimod in relapsing-remitting multiple sclerosis (RRMS), sponsored by Novartis. Started Feb 2012; status: completed.
02
Drugs
fingolimod
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT01497262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01497262.